Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.

Clinical trial NCT06762431 · RECRUITING

Trial details

NCT number: NCT06762431
Sponsor: Vitebsk Regional Clinical Cancer Centre
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukaemia (CLL)Small Lymphocytic Lymphoma (SLL)

Start date: 2024-05-14
Primary completion: 2026-08-09
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.